Free Trial
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Price, News & Analysis

Myriad Genetics logo
$5.44 -0.17 (-2.95%)
As of 10:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Myriad Genetics Stock (NASDAQ:MYGN)

Key Stats

Today's Range
$5.45
$5.61
50-Day Range
$3.84
$7.70
52-Week Range
$3.81
$29.30
Volume
113,072 shs
Average Volume
1.26 million shs
Market Capitalization
$501.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.38
Consensus Rating
Hold

Company Overview

Myriad Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

MYGN MarketRank™: 

Myriad Genetics scored higher than 83% of companies evaluated by MarketBeat, and ranked 166th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 10 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Myriad Genetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Myriad Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Myriad Genetics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Myriad Genetics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Myriad Genetics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Myriad Genetics' valuation and earnings.
  • Percentage of Shares Shorted

    9.31% of the float of Myriad Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Myriad Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Myriad Genetics has recently decreased by 4.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Myriad Genetics does not currently pay a dividend.

  • Dividend Growth

    Myriad Genetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.31% of the float of Myriad Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Myriad Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Myriad Genetics has recently decreased by 4.56%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Myriad Genetics this week, compared to 8 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Myriad Genetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.10% of the stock of Myriad Genetics is held by insiders.

  • Percentage Held by Institutions

    99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Myriad Genetics' insider trading history.
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

MYGN Myriad Genetics, Inc. - Seeking Alpha
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

MYGN Stock Analysis - Frequently Asked Questions

Myriad Genetics' stock was trading at $13.71 at the beginning of the year. Since then, MYGN stock has decreased by 59.2% and is now trading at $5.60.

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The firm's revenue for the quarter was down 33.6% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Myriad Genetics: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and others.

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

Last Earnings
5/06/2025
Today
7/07/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MYGN
Employees
2,700
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$14.38
High Stock Price Target
$30.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+156.9%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.30 million
Pretax Margin
-15.28%

Debt

Sales & Book Value

Annual Sales
$837.60 million
Cash Flow
$1.00 per share
Price / Cash Flow
5.60
Book Value
$7.70 per share
Price / Book
0.73

Miscellaneous

Free Float
90,241,000
Market Cap
$516.21 million
Optionable
Optionable
Beta
1.91

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:MYGN) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners